Phase III failure for pancreatic cancer vaccine hope GV1001
This article was originally published in Scrip
Executive Summary
Hopes for what would have been the first therapeutic vaccine for pancreatic cancer have been dashed by the Phase III failure of KAEL-GemVax's GV1001, forcing the South Korean firm to reconsider the future strategy for its lead development project.